Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC 1 in men with biochemical recurrence of prostate cancer

2024-511430-12-00 Protocol ProSperA_CC-1 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 11 Nov 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol ProSperA_CC-1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 56
Countries 1
Sites 1

Prostate cancer recurrent

Key facts

Sponsor
Universitaetsklinikum Tuebingen AöR
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Male Urogenital Diseases [C12]
Trial duration
11 Nov 2022 → ongoing
Decision date (initial)
2024-03-05
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511430-12-00
EudraCT number
2022-002420-13
ClinicalTrials.gov
NCT05646550

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Prostate cancer recurrent

VersionLevelCodeTermSystem organ class
21.0 PT 10036911 Prostate cancer recurrent 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Tuebingen AöR

Sponsor organisation
Universitaetsklinikum Tuebingen AöR
Address
Geissweg 3, Innenstadt Innenstadt
City
Tübingen
Postcode
72076
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
Helmut Salih

Public contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
Helmut Salih

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 56 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
Universitaetsklinikum Tuebingen AöR
KKE Translationale Immunologie, Otfried-Mueller-Strasse 10, Nordstadt, Tuebingen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2022-11-11 2023-01-10

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-12 Germany Acceptable
2024-02-29
2024-03-05
2 SUBSTANTIAL MODIFICATION SM-1 2025-02-07 Germany Acceptable
2025-03-26
2025-03-26
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-11-06 Germany Acceptable
2025-03-26
2025-11-06
4 SUBSTANTIAL MODIFICATION SM-2 2026-03-10 Germany Acceptable
2026-04-07
2026-04-09